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Bulleted statement.  22 
Most of the literature on TOPFA for congenital heart defects includes single-center hospital-based 23 
studies. Moreover, few studies have evaluated both socioeconomic and clinical factors that could 24 
be associated with the risk of TOPFA for congenital heart defects. 25 
Using population-based data, we found that, in addition to severity of congenital heart defects, 26 
early prenatal diagnosis and maternal characteristics are highly associated with the probability of 27 
TOPFA for isolated congenital heart defects. 28 
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ABSTRACT 43 
Objectives. 1) Evaluate the probability and timing of termination of pregnancy for fetal anomaly 44 
(TOPFA) for all congenital heart defects (CHD) and categories of CHD; 2) assess clinical and 45 
socioeconomic predictors of TOPFA for isolated CHD excluding ventricular septal defects (VSD).  46 
Methods. Using population-based data from the Paris Registry of Congenital malformations, we 47 
assessed the probability of TOPFA and gestational age at TOPFA. We used logistic regression to 48 
estimate the adjusted effects of maternal characteristics, clinical factors (CHD type, fetal growth 49 
restriction, nuchal translucency measurement, and gestational age at prenatal diagnosis) on the 50 
odds of TOPFA. 51 
Results. The  proportion of TOPFA  for prenatally diagnosed CHD was 46% for all CHD 52 
combined,  82% for CHD associated with chromosomal anomalies and 27% for isolated CHD-53 
VSD excluded. Isolated CHD-VSD excluded diagnosed before 22 weeks of gestational age had a 54 
3.2-fold higher odds of TOPFA (Adjusted-OR 3.2, 95%CI 1.4–7.1). Maternal occupation was not 55 
associated with the odds of TOPFA. Women of African origin had a ten-fold lower odds of TOPFA 56 
than women of French origin (Adjusted-OR 0.1, 95% CI 0.02–0.4).  57 
Conclusion. In addition to severity of CHD, early prenatal diagnosis and maternal characteristics 58 
were highly associated with the probability of TOPFA for CHD.   59 
Keywords. Termination of pregnancy for fetal anomaly, prenatal diagnosis, congenital heart 60 
defects, epidemiology, risk factors. 61 
  
INTRODUCTION 62 
Congenital heart defects (CHD) are the most frequent congenital anomalies.1 Progress in fetal 63 
ultrasonography has conducted to an increase in the overall proportion of congenital 64 
malformations, and in particular CHD, that are prenatally diagnosed. The most severe cases of 65 
CHD can be accurately diagnosed during fetal life.2-4 Ultrasonography screening for CHD at 13/14 66 
weeks of gestation has shown to have good performances and has been proposed to be routinely 67 
performed in low-risk population.5 In case of positive screening, a more detailed scan must be 68 
performed by a pediatric cardiologist in the beginning of the second trimester.6 In high risk 69 
population, a specialized scan should be offered in first trimester.7 The overall effect of prenatal 70 
diagnosis on the outcome of fetuses with CHD is difficult to evaluate due to higher severity of 71 
cases that are prenatally diagnosed.8 Nevertheless, the beneficial effect of prenatal diagnosis on 72 
morbidity and mortality has been shown for certain CHD such as transposition of great arteries or 73 
coarctation of the aorta.2,9,10 74 
For the most severe CHD, termination of pregnancy for fetal anomaly (TOPFA) following prenatal 75 
diagnosis may be an option to discuss with parents.6,11,12 Previous studies have shown that timing 76 
and accuracy of prenatal diagnosis, existence of associated anomalies, available treatment options 77 
and prognosis are factors associated with decision-making regarding TOPFA in case of CHD.6,12,13 78 
However, most studies have examined TOPFA for CHD with single-center hospital-based 79 
data11,13,14 and few population-based studies exist regarding TOPFA for CHD.2,3,15 Moreover, few 80 
studies have evaluated both socioeconomic and clinical factors that could be associated with the 81 
risk of TOPFA for CHD.  82 
Using population-based data from the Paris Registry for Congenital Malformations, we 1) 83 
examined the proportion of TOPFA and gestational age at TOPFA for all CHD and categories of 84 
CHD and 2) assessed the role of socioeconomic and clinical factors associated with TOPFA and 85 
  
gestational age at TOPFA for cases of “isolated” CHD excluding ventricular septal defects (i.e., 86 
"major" CHD with no other associated anomalies). 87 
  
MATERIAL AND METHODS 88 
Data 89 
We used data from the Paris Registry for Congenital Malformations which registers all cases of 90 
birth defects and chromosomal anomalies among live-borns, still-borns (≥22 weeks of gestation), 91 
and TOPFA at any gestational age. The Registry covers the population of women who live in 92 
Greater Paris area (Paris and its surrounding suburb) and deliver or have a pregnancy termination 93 
in a Parisian maternity unit. The annual number of deliveries in our population is about 38 000. 94 
The Paris Registry is a member of the European Network of Registries of Congenital 95 
Malformations (EUROCAT)16,17 and of the International Clearinghouse for Birth Defects 96 
Surveillance and Research.18,19 97 
The Registry follows the EUROCAT methodology and quality of data is routinely monitored by 98 
both EUROCAT and the National Committee of Registries in France. The review of procedures 99 
regarding confidentiality of data is overseen by both the National Committee of Registries and the 100 
National Committee of Informatics and Freedom. Data are based on medical records and are 101 
collected from several sources including maternity units, neonatology wards, and cytogenetic and 102 
pathology services.  103 
Our study population comprised women who lived and delivered or had a pregnancy termination 104 
in Paris during the period 2001-2007. 105 
Methods 106 
We conducted an observational study to i) describe the proportion of TOPFA after prenatal 107 
diagnosis and gestational age at TOPFA and ii) assess predictors associated with the risk (odds) of 108 
TOPFA and gestational age at TOPFA. 109 
Proportions of TOPFA and gestational age at TOPFA were estimated for the following categories: 110 
i) all CHD combined, ii) all isolated CHD, iii) isolated CHD-ventricular septal defects (VSD) 111 
  
excluded; the latter category was constituted in order to represent major isolated CHD that often 112 
requires intervention , iv) CHD associated with chromosomal anomalies and v) CHD associated 113 
with malformations of other systems. 114 
Predictors of the odds of TOPFA were assessed for isolated CHD-VSD excluded.  Variables 115 
considered as predictors were maternal characteristics (age, occupation, geographic origin and 116 
gravidity), clinical characteristics (nuchal translucency, intra-uterine growth retardation (IUGR), 117 
gestational age at prenatal diagnosis, gestational age at TOPFA, and category of CHD) and year of 118 
TOPFA. Maternal age was coded in three categories (≤ 34, 35-37, ≥38) based on the higher risk of 119 
chromosomal anomalies in women aged 35 or more and the fact that at the time of our study 120 
reimbursed amniocentesis or chorionic villus sampling was available to all women over 38 years 121 
of age in our study population. Maternal occupation comprised the following categories: 122 
professional, intermediate, administrative/public service, and none. Maternal geographic origin 123 
was coded as: French, African and other countries. Gravidity was coded in two categories: 124 
primigravida and multigravida. Nuchal translucency measured at first trimester scan was 125 
categorized as: normal, abnormal and not done (i.e. women who had not their 1st trimester scan). 126 
IUGR was as noted in medical records and coded in two categories (no/yes). Gestational age at 127 
prenatal diagnosis was dichotomized in gestational age ≤ 22 and >22 weeks, as 22 weeks is the 128 
recommended term for 2nd trimester scan in France. Gestational age at TOPFA was analyzed as a 129 
continuous variable. Isolated cases of CHD were classified into 4 subcategories by a pediatric 130 
cardiologist (T.B.) based on the diagnosis recorded in the Registry database: i) functionally 131 
univentricular CHD, ii) so-called conotruncal CHD, iii) complex CHD (at least two cardiac defects 132 
combined excluding VSD) and iv) other CHD.  133 
 134 
Statistical analyses 135 
  
Data were analyzed using standard descriptive statistics (mean, standard deviation (SD), and 136 
frequency). Chi-square test, or Fisher’s exact test when appropriate, and ANOVA test were used 137 
for univariate analyses of the differences between groups. The associations between clinical and 138 
socioeconomic factors and the odds of TOPFA were assessed using logistic regression models. 139 
Observations with missing values were excluded from the multivariate analyses. The statistical 140 
significance level was set at α = 0.05. All analyses were done with Stata 10 software (Statacorp, 141 
TX, USA). 142 
 143 
RESULTS  144 
During the study period, 1465 cases of CHD were registered, among which 66% (n=968) were 145 
isolated CHD, 16% (n=230) were CHD associated with chromosomal anomalies and 18% (n=267) 146 
with anomalies of other systems (including genetic syndromes). VSD accounted for half of the 147 
cases of isolated CHD (51%, n = 495).  148 
Gestational age at prenatal diagnosis was missing for 0.4% of fetuses. There were no missing data 149 
for the outcome of the pregnancy (live-birth, still-birth, TOPFA). Maternal occupation and nuchal 150 
translucency were missing for 8% of cases.  For the other variables, data were missing for less than 151 
1% of fetuses. 152 
Table 1 summarizes the proportions of prenatal diagnosis and TOPFA for all CHD, and 153 
subcategories of CHD. Overall, 48% (703/1465) of cases were prenatally diagnosed and TOPFA 154 
occurred for 22% of all cases of CHD (325/1465). Prenatal diagnosis was made for 35% of all 155 
isolated CHD (339/968), 58% of isolated CHD - VSD excluded (274/473) and 79% of CHD 156 
associated with chromosomal anomalies (182/230). 157 
Among prenatally diagnosed CHD (n=703), TOPFA was performed in 46% (325/703) of cases. 158 
The highest proportion of TOPFA was observed for CHD associated with chromosomal anomalies 159 
  
(82%, 148/182). CHD associated with chromosomal anomalies accounted for 45% of cases of 160 
TOPFA (148/325). Proportion of TOPFA for isolated CHD - VSD excluded was 27% (74/274). 161 
Among those 74 cases of TOPFA for isolated CHD - VSD excluded, hypoplastic left heart 162 
syndrome accounted for half (51%, n=38).  163 
Overall, the mean gestational age at prenatal diagnosis was 20.4 weeks (SD 0.26) for the study 164 
population (Table 2). Mean gestational age at prenatal diagnosis was lowest for cases associated 165 
with chromosomal anomalies (19.1, SD 0.38) and highest for isolated CHD - VSD excluded (21.9, 166 
SD 0.39). The mean gestational age at TOPFA was 23.2 weeks (SD 0.29) for the study population 167 
(Table 2). The average gestational age at TOPFA was lowest for CHD associated with 168 
chromosomal anomalies (21.7, SD 0.45) and highest for isolated CHD - VSD excluded (24.8, SD 169 
0.46). The mean duration between prenatal diagnosis and TOPFA was 2.8 weeks and was similar 170 
for all subcategories of CHD. More than half (57%) of TOPFA for CHD associated with 171 
chromosomal anomalies were performed before 22 weeks of gestation vs. 17% for isolated CHD - 172 
VSD excluded. We did not find a significant time trend in the  gestational age at TOPFA over the 173 
study period. 174 
Table 3 summarizes the univariate analyses of the association of TOPFA for isolated CHD - VSD 175 
excluded with maternal characteristics and clinical factors. TOPFA was significantly less frequent 176 
for mothers of African origin (11% vs. 33% for mother of French origin and 28% for women of 177 
other origin, p=0.003). TOPFA was significantly more frequent for CHD diagnosed before 22 178 
weeks of gestation (42% vs. 17% for CHD diagnosed after 22 weeks, p<0.001), for functionally 179 
univentricular CHD and complex CHD (60% and 34 % respectively vs. 21% for conotruncal CHD 180 
and 11% for other CHD, p<0.001). No statistically significant associations were observed for the 181 
other factors, although TOPFA tended to be more frequent in case of IUGR (50% vs. 26%, 182 
p=0.09).  183 
  
Table 4 summarizes the multivariate analyses of the association of TOPFA for isolated CHD - 184 
VSD excluded with maternal characteristics and clinical factors. CHD diagnosed before 22 weeks 185 
of gestational age had a 3.2- fold higher odds of TOPFA than those diagnosed later (adjusted OR 186 
3.2, 95%CI 1.4 – 7.1). IUGR (adjusted OR 6.6, 95%CI 0.9 – 51.0), single ventricle (adjusted OR 187 
21.3, 95%CI 7.7 – 59.0) and complex CHD (adjusted OR 5.8, 95%CI 1.7 – 17.4) were also 188 
associated with higher odds of TOPFA but confidence intervals were fairly wide. Maternal 189 
occupation was not associated with the odds of TOPFA. However women of African origin had a 190 
10-fold lower odds of TOPFA than women of French origin (adjusted OR 0.1, 95% CI 0.02 – 0.4). 191 
There was no significant timr trend in the odds of TOPFA during the study period. 192 
Table 5 summarizes the results of the univariate analyses of predictors of mean gestational age at 193 
TOPFA. Sample sizes were relatively small and no statistically significant associations were 194 
observed. In particular maternal characteristics were not significantly associated with gestational 195 
age at TOPFA whereas an increased nuchal translucency measurement tended to be associated with 196 
a lower gestational age at TOPFA although the association was not statistically significant 197 
(p=0.13). 198 
 199 
  
DISCUSSION 200 
Using population-based data from the Paris Registry for Congenital Malformations, we found that 201 
the overall rate of termination of pregnancy for fetal anomaly (TOPFA) for cases with congenital 202 
heart defects (CHD) prenatally diagnosed was 46%. The highest probability of TOPFA was 203 
observed for CHD associated with chromosomal anomalies (82%). A prenatal diagnosis before 22 204 
weeks of gestation was associated with a 3.2-higher odds of TOPFA for isolated CHD - VSD 205 
excluded. Maternal occupation was not independently associated with the probability of TOPFA. 206 
However, mothers of African origin had a 10 fold-lower odds of TOPFA than women of French 207 
origin.  208 
It is difficult to know the extent to which our results may be generaliseable to other countries. 209 
France represents a particular context for prenatal diagnosis and TOPFA as it pursues an active and 210 
highly codified policy of prenatal diagnosis. In contrast to many European countries, TOPFA is 211 
authorized in France regardless of gestational age for incurable fetal diseases or life-threatening 212 
maternal conditions.20 Proportions of prenatal diagnosis and TOPFA, in particular for CHD, tend 213 
to be higher in France as compared to those observed in other countries1,15,16 even though 214 
differences in the post-natal diagnosis and the period of registration of cases in the postnatal period 215 
across countries complicate the interpretation of observed differences in the proportion of prenatal 216 
diagnosis for CHD in different countries.  217 
We observed a lower proportion of TOPFA for isolated CHD as compared to CHD associated with 218 
chromosomal anomalies or anomalies of other systems, which is consistent with the data from the 219 
European surveillance of congenital anomalies (Eurocat) network of registries of congenital 220 
anomalies.4,21 We also observed that the risk of TOPFA was significantly higher for functionally 221 
univentricular CHD, which is due to the fact that the outcomes for functionally univentricular 222 
CHD remain poor.22,23 223 
  
Socioeconomic factors are known to be associated with the likelihood of TOPFA for chromosomal 224 
anomalies, in particular Down syndrome.24-27 This association has been little studied in the specific 225 
case of CHD.27 In a hospital-based study, Zyblewski et al.13 did not find an association between 226 
socioeconomic factors and TOPFA. We found that maternal geographic origin, but not occupation, 227 
was strongly associated with the risk of TOPFA for isolated CHD. Access to information about 228 
prenatal diagnosis and TOPFA and parental decision making for chromosomal anomalies have 229 
been shown to be influenced by preferences and cultural factors26,28, although the barriers to 230 
effective access to full information may also include language barrier since interpreters are often 231 
not available. The same association between TOPFA and cultural factors may exist for isolated 232 
CHD. We did not observe an association between maternal age and the probability of TOPFA for 233 
isolated CHD, suggesting that the overall higher rates of TOPFA for CHD in older women were 234 
due to the higher proportions of associated chromosomal anomalies. Prenatal diagnosis and 235 
TOPFA occurred earlier in case of CHD associated with chromosomal anomalies.28,29 This may 236 
have been in part due to an increased nuchal translucency measured in the first trimester which is 237 
more likely to occur for both chromosomal anomalies and certain CHD. It is also possible that 238 
even in the absence of an increased nuchal translucency, cytogenetic studies conducted after  239 
prenatal diagnosis of a CHD diagnosed earlier in pregnancy were more likely to reveal an 240 
associated chromosomal anomaly. 241 
The average interval between prenatal diagnosis and TOPFA was similar (two weeks) for both 242 
isolated CHD and CHD associated with chromosomal anomalies and  was consistent with other 243 
studies.4,29 This interval corresponds to the time necessary for a multidisciplinary discussion and 244 
for parents to make their decision. 245 
The proportion of TOPFA in fetuses with CHD has been shown to be higher when prenatal 246 
diagnosis occurs earlier.4,5,12 We also found that isolated CHD - VSD excluded diagnosed before 247 
  
22 weeks had a 3.2-fold higher odds of TOPFA in comparison to those diagnosed later. TOPFA 248 
may indeed be more easily accepted by families at an earlier gestational age.4In addition, CHD 249 
diagnosed earlier may have been on average more severe (associated with poorer prognosis) and 250 
hence be more likely to be a candidate for TOPFA. Even though we partially took into account 251 
severity of CHD in our analyses, a residual effect of severity as one explanation for the association 252 
between earlier timing of prenatal diagnosis and probability of TOPFA cannot be excluded.  253 
For isolated CHD - VSD excluded, gestational age at TOPFA tended to be lower in case of 254 
abnormal nuchal translucency. Indeed, a more detailed examination of fetal heart is usually 255 
performed after an abnormal nuchal translucency measurement on first trimester ultrasonography 256 
and may therefore conduct to the earlier diagnosis of a CHD.30,31 257 
Our study has certain limitations. Due to small sample sizes, confidence intervals were fairly wide 258 
indicating the limited precision of our estimates. We did not adjust for paternal characteristics due 259 
to a high frequency of missing data. Nevertheless, paternal characteristics are strongly correlated 260 
with maternal characteristics and are therefore, at least partially, taken into account by maternal 261 
adjustment. Data were complete for pregnancy outcome and there were few missing data for the 262 
factors included in the analyses. Bias in our estimates due to missing data is therefore unlikely. 263 
However, residual bias or residual confusion due to missing data or confounding factors not taken 264 
into account in this study cannot be excluded. The strengths of our study are a large sample size 265 
and population-based data. 266 
We explored specific associations that may exist between the risks of TOPFA and different 267 
categories of CHD defined a priori based on anatomic and/or clinical criteria and classified by a 268 
pediatric cardiologist. A caveat that needs to be considered is that our criteria for defining these 269 
categories can be arguable. Moreover, alternative and more detailed groupings exist32,33, which 270 
may provide additional information for estimating the probability of TOPFA for CHD. However, 271 
  
our results suggest that specific associations exist between the categories of CHD as defined in our 272 
study and the probability of TOPFA without necessarily implying that the categories investigated 273 
in our study are the most appropriate ones to use in this setting.  274 
Diagnostic bias may have occurred as not all fetuses with a prenatally diagnosed CHD resulting in 275 
TOPFA had a fetal pathology examination. Therefore, in these cases ascertainment of CHD was 276 
based only on prenatal findings. Nevertheless, these cases represented a minority of the overall 277 
study population.  278 
 279 
CONCLUSION. 280 
In conclusion, TOPFA occurred for 27% of isolated CHD - VSD excluded that were prenatally 281 
diagnosed, 82% of CHD associated with chromosomal anomalies and 53% of CHD associated 282 
with anomalies of other systems. Prenatal diagnosis of isolated CHD - VSD excluded before 22 283 
weeks of gestation was associated with a 3.2-fold higher odds of TOPFA.  Women of African 284 
origin had a 10-fold lower odds of TOPFA than women of French origin. The categories of CHD 285 
reflecting its severity were also significantly associated with the risk of TOPFA for isolated CHD - 286 
VSD excluded. Gestational age at TOPFA tended to be earlier in fetuses with an abnormal nuchal 287 
translucency. Timing of TOFPA was explained essentially by timing of prenatal diagnosis and the 288 
time interval between prenatal diagnosis and TOPFA appeared to be essentially constant for all the 289 
clinical and socioeconomic categories included in our study. 290 
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n Prenatal diagnosis
% 95% CI % 95% CI
All CHD 1465 48 46 - 51 46 42 - 50
All Isolated CHD 968 35 32 - 38 16 12 - 19
Isolated CHD-VSD excluded 473 58 54 - 63 27 22 - 32
   functionally univentricular CHD 68 93 86 - 99 60 48 - 72
   conotruncal defect 53 72 59 - 84 21 8 - 34
   complex CHD 48 85 75 - 95 34 19 - 49
   other CHD 304 44 38 - 50 11 5 - 16
CHD associated with chromosomal anomalies 230 79  74 - 84 82 77 - 88
CHD associated with anomalies of other systems* 267 73 67 - 78 53  46 - 60
* including genetic syndromes
Table 1. Prenatal diagnosis and termination of pregnancy for fetal anomaly (TOPFA) for fetuses with congenital heart defects (CHD).
Proportion of TOPFA among cases 
with a prenatal diagnosis
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All CHD p
Gestational age at prenatal diagnosis (weeks)
   mean (SD*) 20.4 (0.26) 21.9 (0.39) 19.1 (0.38) 21 (0.51) < 0.001
21 (17 - 23) 22 (21 - 23) 18 (16 - 22.5) 22 (18 - 23) < 0.001
Gestational age at termination of pregnancy (weeks)
   mean (SD*) 23.2 (0.29) 24.8 (0.46) 21.7 (0.45) 24.1 (0.55) < 0.001
23 (19 - 26) 25 (23 - 26) 21.5 (18 - 25) 24 (20 - 28) < 0.001
   ч ϮϮ 40% 17% 57% 34%
< 0.001   23 - 25 30% 45% 22% 30%
   ш Ϯϲ 30% 38% 21% 36%
   mean (SD*) 2.8 (0.14) 2.8 (0.26) 2.6 (0.21) 3.1 (0.3) 0.4
2 (1 - 3) 2 (1 - 4) 2 (1 - 3) 2 (1 - 4) 0.6
Table 2. Gestational age at prenatal diagnosis and at termination of pregnancy in fetuses with congenital heart defects.
Isolated CHD – VSD 
excluded
CHD associated with 
chromosomal anomalies
CHD associated with   anomalies 
of other systems
   median (IQR§)
   median (IQR§)
Time interval between prenatal diagnosis and termination 
of pregnancy (weeks)
   median (IQR§)
*SD : standard deviation
§ IQR : interquartile range (25th percentile – ϳϱth percentile)
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n % of TOPFA 95% CI p
Maternal age
   ч ϯϰ 184 24 18 - 31
0.5   35 - 37 43 32 18 - 47
   ш ϯϴ 47 30 16 - 43
Gravidity
   primigravida 99 27 20 - 33
0.8
   multigravida 175 26 18 - 36
Maternal geographic origin
   France 152 33 25 - 40
0.003   Africa 66 11 3 - 18
   Other 56 28 16 - 40
Maternal occupation
   professional 91 31 21 - 40
0.12
   intermediate 36 25 11 - 39
   administrative / public service 51 25 13 - 38
   none 74 15 6 - 23
Intra-uterine growth retardation
   no 265 26 21 - 31
0.09
   yes 10 50 17 - 82
Nuchal translucency measurement
   normal 206 28 22 - 34
0.27   abnormal 17 35 12 - 59
   not measured 31 16 3 - 29
Gestational age at prenatal diagnosis (weeks)
   > 22 167 17 11 - 23
<0.001   ч ϮϮ 108 42 32 - 51
Category of CHD 
   other 133 11 5 - 16
<0.001
   functionally univentricular CHD 63 60 48 - 72
   conotruncal CHD 38 21 8 - 34
   complex CHD 41 34 19 - 49
Table 3. Association between the odds of TOPFA and maternal socioeconomic and clinical factors in fetuses with isolated CHD-VSD 
excluded.
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Unadjusted OR 95% CI Adjusted OR 95% CI
Maternal age
   ч ϯϰ 1.0 ref. 1.0 ref.
   35 - 37 1.5 0.7 - 3.1 1.0 0.3 - 3.2
   ш ϯϴ 1.3 0.6 - 2.7 1.5 0.5 - 4.0
Maternal geographic origin
   France 1.0 ref. 1.0 ref.
   Africa 0.2 0.1 - 0.6 0.1 0.02 - 0.4
   Other 0.8 0.4 - 1.6 0.8 0.3 - 2.3
Maternal occupation
   professional 1.0 ref. 1.0 ref.
   intermediate 0.7 0.3 - 1.8 0.7 0.2 - 2.2
   administrative / public service 0.8 0.3 - 1.7 1.2 0.4 - 3.6
   none 0.4 0.2 - 0.8 0.5 0.1 - 1.6
Intra-uterine growth retardation
   no 1.0 ref. 1.0 ref.
   yes 2.8 0.8 - 10.1 6.6 0.9 - 51.0
Nuchal translucency measurement
   normal 1.0 ref. 1.0 ref.
   abnormal 1.3 0.5 - 3.9 1.5 0.3 - 6.2
   not measured 0.5 0.2 - 1.3 1.2 0.2 - 5.0
Gestational age at prenatal diagnosis
   > 22 1.0 ref. 1.0 ref.
   ч ϮϮ 3.4 1.9 - 5.9 3.2 1.4 - 7.1
Category of CHD 
   other 1.0 ref. 1.0 ref.
   functionally univentricular CHD 12.9 6.1 - 27.3 21.3 7.7 - 59.0
   conotruncal CHD 2.3 0.9 - 5.9 2.1 0.7 - 6.6
   complex CHD 4.4 1.9 - 10.3 5.7 1.8 - 17.4
Table 4. Logistic regression analyses of the association between the odds of TOPFA and maternal socioeconomic and clinical factors in 
fetuses with prenatally diagnosed isolated CHD-VSD excluded.
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n SD p
Maternal age 
   ч ϯϰ 45 24.7 0.5
0.9   35 - 37 14 24.5 1.2
   ш ϯϴ 14 25.6 1.3
Gravidity
   Primigravida 27 24.0 0.5
0.2
   Multigravida 46 25.3 0.7
Maternal geographic origin
   France 50 24.8 0.6
0.8   Africa 7 24.0 1.7
   Other 16 25.1 0.9
Maternal occupation
   professional 28 24.3 0.8
0.4
   intermediate 9 27.1 1.6
   administrative / public service 13 25.1 1.1
   none 11 24.8 0.9
Intra-uterine growth retardation
   no 69 24.8 0.5
0.7
   yes 5 24.2 1.6
Nuchal translucency measurement
   normal 58 25.3 0.5
0.13   abnormal 6 22.0 1.1
   not measured 5 24.8 2.0
Type of CHD 
   other 14 24.2 1.3
0.13
   functionally univentriclar CHD 38 25.2 0.6
   conotruncal CHD 8 26.9 1.3
   complex CHD 14 23.1 1.1
Table 5. Association between gestational age at TOPFA and maternal socioeconomic and clinical factors in fetuses with 
isolated CHD-VSD excluded.
mean               
gestational age
